125 SEC-IND Office order dated 31.01.2024 2024-Jan-31 182 KB
In force — no superseding record on file.
Directorate General of Health Services Central Drugs Standard Control Organization (Expert Committee Coordination Division)
FDA Bhawan, New Delhi Dated: “3-o- 2624
NOTICE
It has now been decided that the meetings of Investigational New Drugs (IND) for evaluation of IND proposals will be conducted by SEC division as per the procedures followed.
In this regard, applicants are requested that the copy of presentation must be submitted through e-vartalap (Sugam Portal) only to concerned division well in advance, after receipt of the invitation letter from CDSCO.
This is for compliance with immediate effect.
Ankit Sharma Deputy Drugs Controller (India)
To,
,
All Stakeholders & CDSCO website.
Verbatim extracted text (OCR/PDF). Older scans and tables may show extraction artifacts — verify against the original for anything you act on.
No analysis generated for this document yet (analysis runs over brief docs + on-demand). Run build_analysis.py --ids 25705 --apply.